Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 131, Issue 2, 2007, Pages 198-202

  Špaček, Jiří ^a   Buchta, Vladimír ^a,b   Jílek, Petr ^b   Förstl, Miroslav ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Hormonal status; Recurrent vulvovaginal candidiasis; Serum progesterone; Symptoms and signs; Urinary pregnanediol

Indexed keywords

PREGNANEDIOL; PROGESTERONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LUTEAL PHASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RECURRENT DISEASE; SYMPTOMATOLOGY; VAGINA CANDIDIASIS;

EID: 33947415700     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.03.009     Document Type: Article

References (34)

1. Odds F.C. Genital candidosis. In: Odds F.C. (Ed). Candida and candidosis: a review and bibliography. 2nd ed. (1988), Bailliere Tindall, London 124-135
2. Ringdahl E.N. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 61 (2000) 3306-3312
3. Spacek J., and Buchta V. Itraconazole in the treatment of acute and recurrent vulvovaginal candidiasis: comparison of a one-day and a three-day regimen. Mycoses 48 (2005) 165-171
4. Corrigan E.M., Clancy R.L., Dunkley M.L., Eyers F.M., and Beagley K.W. Cellular immunity in recurrent vulvovaginal candidiasis. Clin Exp Immunol 111 (1998) 574-578
5. Fidel Jr. P.L. History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12 (2004) 220-227
6. Fidel Jr. P.L., Cutright J., and Steele C. Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun 68 (2000) 651-657
7. Kalo-Klein A., and Witkin S.S. Candida albicans: cellular immune system interactions during different stages of the menstrual cycle. Am J Obstet Gynecol 161 (1989) 1132-1136
8. Sobel J.D. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Infect Dis Rep 4 (2002) 514-519
9. Zhang X., Essmann M., Burt E.T., and Larsen B. Estrogen effects on Candida albicans: a potential virulence-regulating mechanism. J Infect Dis 181 (2000) 1441-1446
10. Spinillo A., Capuzzo E., Acciano S., De Santolo A., and Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 180 (1999) 14-17
11. Larsen B., and Galask R.P. Estrogen and normal flora on vaginal candidiasis in the rat. J Reprod Med 29 (1984) 863-868
12. Kinsman O.S., and Collard A.E. Hormonal factors in vaginal candidiasis in rats. Infect Immun 53 (1986) 498-504
13. Segal E., Soroka A., and Schechter A. Correlative relationship between adherence of Candida albicans to human vaginal epithelial cells in vitro and candidal vaginitis. Sabouraudia 22 (1984) 191-200
14. Kalo A., and Segal E. Interaction of Candida albicans with genital mucosa: effect of sex hormones on adherence of yeasts in vitro. Can J Microbiol 34 (1988) 224-228
15. Glazener C.M., Bailey I., and Hull M.G.R. Effectiveness of vaginal administration of progesterone. Am J Obstet Gynecol 92 (1985) 364-368
16. Blackwell L.F., Brown J.B., and Cooke D. Definition of potentially fertile period from urinary steroids excretion rates. Part II. A threshold value for pregnandiol glucuronide as a marker for the end of the potentially fertile period in the human menstrual cycle. Steroids 63 (1998) 5-13
17. Malcolm C.E., and Cumming D.C. Does anovulation exist in eumenorrheic women?. Obstetrics & Gynecology 102 (2003) 317-318
18. Buchta V., and Spacek J. Microbiological findings in patients with recurrent vulvovaginal candidiasis in Faculty Hospital Hradec Kralove in the years 1995-2002 [in Czech]. Ces Gynek 69 (2004) 7-14
19. Fong I.W., Bannatyne R.M., and Wong P. Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole, and clotrimazole in woman treated for recurrent vulvovaginal candidiasis. Genitourin Med 69 (1993) 44-46
20. Lynch M.E., Sobel J.D., and Fidel Jr. P.L. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 34 (1996) 337-339
21. Oriel J.D., Partridge B.M., Denny M.J., et al. Genital yeast infections. Br Med J 4 (1988) 761-764
22. Spinillo A., Capuzzo E., Nicola S., Baltaro F., Ferrari A., and Monaco A. The impact of oral contraception on vulvovaginal candidiasis. Contraception 51 (1995) 293-297
23. Nelson A.L. The impact of contraceptive methods on the onset of symptomatic vulvovaginal candidiasis within the menstrual cycle. Am J Obstet Gynecol 176 (1997) 1376-1380
24. Fidel Jr. P.L., and Sobel J.D. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 9 (1996) 335-348
25. Barousse M.M., Steele C., Dunlap K., et al. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 184 (2001) 1489-1493
26. Jilek P., Spacek J., Buchta V., et al. Systemic immunity in patients with recurrent vulvovaginal candidiasis [in Czech]. Ces Gynek 70 (2005) 453-459
27. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Inf 74 (1998) 11-19
28. Larsen B., and Galask R.P. Influence of estrogen and normal flora on vaginal candidiasis in the rat. J Reprod Med 29 (1984) 863-868
29. McCourtie J., and Douglas L.G. Relationship between cell surface composition of Candida albicans and adherence to acrylic after-growth on different carbon sources. Infect Immun 32 (1981) 1234-1241
30. Loose D.S., and Feldman D. Characterization of a unique corticosterone binding protein in Candida albicans. J Biol Chem 257 (1982) 4925-4930
31. White S., and Larsen B. Candida albicans morphogenesis is influenced by estrogen. Cell Mol Life Sci 53 (1997) 744-749
32. Dennerstein G. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 31 (1986) 801-803
33. Kalo-Klein A., and Witkin S.S. Regulation of the immune response to Candida albicans by monocytes and progesterone. Am J Obstet Gynecol 164 (1991) 1351-1354
34. Nohmi T., Abe S., Dobashi K., Tansho S., and Yamaguchi H. Suppression of anti-Candida activity of murine neutrophils by progesterone in vitro: a possible mechanism in pregnant women's vulnerability to vaginal candidiasis. Microbiol Immunol 39 (1995) 405-409